Lipodox 50mg Injection

• Breast cancer
• Ovarian cancer
• Bladder cancer
• Lung  cancer
• Stomach cancer
• Multiple myeloma
• AIDS-related Kaposi’s sarcoma

Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Lipodox 50mg Injection  can also have adverse effects on the body, most of which resolve without the need for medical attention.

Some common side effects include:

• Low blood cell counts
• Hair loss
• Decreased appetite
• Skin rashes
• Pain in the muscles and joints
• Constipation
• Feeling confused, difficulty sleeping
• Headache, dizziness, sleepiness
• Change in taste
• High or low blood pressure
• Excessive sweating
• Pain when passing urine
• Weight loss
• Muscle spasms
• Fast heartbeat

Seek medical attention in case of any unusual or severe side effects immediately.

• Lipodox 50mg Injection is a powerful anticancer medicine that can only be given intravenously by a doctor or nurse under strict medical supervision. It is not self-administerable.
• Dosage and duration of the treatment are determined by the doctor as per the patient's health condition and type & stage of the cancer.
  
  

• Lipodox 50mg Injection is a chemotherapy based anti-cancer medication. It contains Doxorubicin Lliposomal as its active ingredient.
• It works by inhibits the activity of the enzyme topoisomerase II, which is involved in the DNA (genetic material) multiplication of cancer cells to slow down the progression of cancer. Thereby prevent the growth & multiplication of abnormal cells.​​
  

• Wolfe, J. L., Thoma, L. A., Du, C., Goldspiel, B. R., Gallelli, J. F., Grimes, G. J., & Potti, G. K. (1999). Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection. American journal of health-system pharmacy, 56(10), 985-989. https://pubmed.ncbi.nlm.nih.gov/10365723/
• Nakada, T., Akiya, T., Yoshikawa, M., Koike, H., & Kayayama, T. (1985). Intravesical instillation of doxorubicin hydrochloride and its incorporation into bladder tumors. The Journal of urology, 134(1), 54-57. https://pubmed.ncbi.nlm.nih.gov/4009823/
• Schwartz, G. K., & Casper, E. S. (1995). A phase II trial of doxorubicin HCl liposome injection in patients with advanced pancreatic adenocarcinoma. Investigational new drugs, 13(1), 77-82.
• Cox, R. F. (1984). Managing skin damage induced by doxorubicin hydrochloride and daunorubicin hydrochloride. American Journal of Hospital Pharmacy, 41(11), 2410-2414. https://pubmed.ncbi.nlm.nih.gov/6150636/
• Burade, V., Bhowmick, S., Maiti, K., Zalawadia, R., Ruan, H., & Thennati, R. (2017). Lipodox®(generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx®(doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models. BMC cancer, 17(1), 405.